This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hensel, F. Articles by Vollmers, H. P. Search for Related Content PubMed PubMed Citation Articles by Hensel, F. Articles by Vollmers, H. P.

Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis¹

Institut für Pathologie, D-97080 Würzburg [F. H., R. H., C. S., N. A., K. S., A. F., H. K. M-H., H. P. V.], and European Molecular Biology Laboratory, D-69012 Heidelberg [A. S., M. M.], Germany

The human monoclonal antibody SC-1 induces apoptosis of stomach carcinoma cells and is currently used in a clinical Phase II trial. The antibody binds to a target molecule that is preferentially expressed on diffuse- and intestinal-type stomach cancer cells and shows a very restricted expression on other normal and malignant tissues. In this paper, we show that the SC-1 receptor is a stomach carcinoma-associated isoform of CD55 [membrane-bound decay-accelerating factor (DAF)-B] with a relative molecular mass of approximately 82 kDa. The antigenic site of SC-1 is an N-linked carbohydrate residue. Cross-linking of the DAF receptor increases apoptotic activity. SC-1 binding induces tyrosine phosphorylation of three proteins of approximately 60, 75, and 110 kDa, whereas a serine residue of an approximately 35-kDa protein is dephosphorylated. Expression of caspase-3 (CPP32) and caspase-8 (FLICE) is elevated, and activation of these caspases occurs. These data show that a tumor-specific variant form DAF is involved in apoptosis and can be used for adjuvant therapeutical purposes on gastric carcinoma.

This article has been cited by other articles:

				S. Brandlein, N. Rauschert, L. Rasche, A. Dreykluft, F. Hensel, E. Conzelmann, H.-K. Muller-Hermelink, and H. P. Vollmers The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein Mol. Cancer Ther., January 1, 2007; 6(1): 326 - 333. [Abstract] [Full Text] [PDF]

				J. Liu, T. Miwa, B. Hilliard, Y. Chen, J. D. Lambris, A. D. Wells, and W.-C. Song The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo J. Exp. Med., February 22, 2005; 201(4): 567 - 577. [Abstract] [Full Text] [PDF]

				P. Carter, L. Smith, and M. Ryan Identification and validation of cell surface antigens for antibody targeting in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687. [Abstract] [Full Text] [PDF]

				T. Pohle, S. Brandlein, N. Ruoff, H. K. Muller-Hermelink, and H. P. Vollmers Lipoptosis: Tumor-Specific Cell Death by Antibody-Induced Intracellular Lipid Accumulation Cancer Res., June 1, 2004; 64(11): 3900 - 3906. [Abstract] [Full Text] [PDF]

				S. Brandlein, T. Pohle, N. Ruoff, E. Wozniak, H.-K. Muller-Hermelink, and H. P. Vollmers Natural IgM Antibodies and Immunosurveillance Mechanisms against Epithelial Cancer Cells in Humans Cancer Res., November 15, 2003; 63(22): 7995 - 8005. [Abstract] [Full Text] [PDF]

				S. Brandlein, I. Beyer, M. Eck, W. Bernhardt, F. Hensel, H. K. Muller-Hermelink, and H. P. Vollmers Cysteine-rich Fibroblast Growth Factor Receptor 1, a New Marker for Precancerous Epithelial Lesions Defined by the Human Monoclonal Antibody PAM-1 Cancer Res., May 1, 2003; 63(9): 2052 - 2061. [Abstract] [Full Text] [PDF]

				T Inoue, M Yamakawa, and T Takahashi Expression of complement regulating factors in gastric cancer cells Mol. Pathol., June 1, 2002; 55(3): 193 - 199. [Abstract] [Full Text] [PDF]